Investigational drug · Phase 2
SIM0278
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Atopic Dermatitis (AD).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SIM0278"
First trial start
2025
Oct 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SIM0278", any sponsor or status.
Conditions studied
As listed on its trial records.
- Atopic Dermatitis (AD)
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "SIM0278" as an intervention, largest first.
- A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT07175233 · 184 participants · Start Oct 28, 2025 · Primary completion Sep 23, 2026
Drug: SIM0278 injection · For: Atopic Dermatitis (AD)
Sites: Hangzhou, China; Shenyang, China
- A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus NephritisNot yet recruiting
Simcere Pharmaceutical Co., LtdAcademic, hospital or other
NCT07393451 · 60 participants (planned) · Start Mar 31, 2026 · Primary completion Mar 31, 2028
Drug: SIM0278 injection · For: Lupus Nephritis
Sites: Beijing, China
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT06022354 · 60 participants · Start Aug 23, 2023 · Primary completion Mar 18, 2025
Drug: SIM0278 Injection/Placebo · For: Healthy Volunteers
Sites: Qingdao, China
Newest research
PubMed records naming it or its code names, newest first.
- SIM0278, an IL-2 mutein that selectively expands regulatory T cells for the treatment of autoimmune disorders.
Yan Y, Yan W, Gao Z, et al. · Front Immunol 2026
Also in development for Atopic Dermatitis (AD)
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- QY201Phase 33 trials
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. · Adult Subjects With Non-Segmental Vitiligo, Atopic Dermatitis (AD), Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
- BFB759Phase 32 trials
Bluefin Biomedicine, Inc. · Atopic Dermatitis (AD), Hidradenitis Suppurativa (HS)
- MH004Phase 32 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Vitiligo, Atopic Dermatitis (AD)
- GS101Phase 31 trial
Jiangsu Genscend Biopharmaceutical Co., Ltd · Atopic Dermatitis (AD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.